Ohm. Any thoughts on the likely maraviroc patent expiration coming soon With regards to efficacy and safety, would leronlimab still be preferred by gov regulators, insurance, and physicians if it cost 5x more than a generic maraviroc. Also if maraviroc patent expires, can it be used instead of leronlimab for conditions where cydy has a patent on the clinical indication. What about someone trying to knockout the ccr5 gene in humans as another circumventing strategy. Is leronlimab as a immunomodulator clinically superior and safer than someone with a homozygous ccr5 deletion